Latest News - Merck KGaA
Top Corporates Hub
Merck KGaA
Zai Lab: Xacduro And ZL-1310 Drive Growth Narrative
06.04.2026 09:02
Zai Lab Limited stock breaks its downtrend on Amgen partnership news and strong drug sales. Click for more on ZLAB stock prospects and see why I am bullish.
Merck & Co. (MRK) Announces Detailed Results From the Phase 2 CADENCE Study
02.04.2026 13:36
Merck & Co., Inc. (NYSE:MRK) is one of the best pharma stocks to invest in now. On March 29, Merck & Co., Inc. (NYSE: MRK) announced detailed results from the Phase 2 CADENCE study designed to evaluate the efficacy, safety, and tolerability of two doses of WINREVAIR™ to treat adults with the syndrome of combined […]
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
02.04.2026 11:01
Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases Study will be sponsored and conducted by Incyte; Adagene to provide clinical supply of muzastotug Collaboration provides additional validation of muzastotug as a potential backbone therapy for next-generation immuno-oncology combinations SAN DIEGO and SUZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the disco
Merck KGaA acquires JSR chromatography business
02.04.2026 10:50
The acquisition will add Belgium-based chromatography operations and a team of over 50 employees to Merck.
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
02.04.2026 10:50
RAHWAY, N.J., April 02, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of a pivotal Phase 2b/3 trial evaluating MK-8748 (also known as Tiespectus, EYE201), a novel investigational bispecific antibody that directly activates Tie2 signaling and inhibits vascular endothelial growth factor (VEGF), for the treatment of neovascular (wet) age-related macular degeneration (NVAMD).
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
02.04.2026 10:45
RAHWAY, N.J., April 02, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA® (pembrolizumab), in combination with paclitaxel, with or without bevacizumab, is approved in the European Union (EU) for the treatment of platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma in adults whose tumors express PD-L1 with a Combined Positive Score (CPS) ≥1 and who have received one or two prior systemic treatment regimens. Thi
Merck Says EU Approves KEYTRUDA, In Combination With Paclitaxel, With Or Without Bevacizumab, For Treatment Of Platinum-Resistant Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma In Adults
02.04.2026 06:48
The KEYTRUDA regimen is the first and only PD-1 inhibitor-based treatment approved in the European Union for these patientsApproval supported by data from the Phase 3 KEYNOTE-B96 trial in which the KEYTRUDA regimen
Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9
02.04.2026 05:54
Merck & Co., Inc. (NYSE:MRK) is one of the 10 Top Stocks Fund Managers Are Loading Up On in 2026. On March 30, 2026, Merck & Co., Inc. (NYSE:MRK) announced positive Phase 3 CORALreef AddOn trial results for enlicitide decanoate, an investigational once-daily oral PCSK9 inhibitor. The study was presented at the American College of […]
How Merck's New Cholesterol Buster Will 'Move The Needle' 'By Removing The Needle'
30.03.2026 15:45
Merck's experimental cholesterol buster easily outperformed a triplet of medications, the Dow Jones component said Monday.
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins
30.03.2026 15:45
RAHWAY, N.J., March 30, 2026--Enlicitide, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions Compared to Oral Non-Statin Therapies
Merck’s strategic shift: acquires Terns for $6.7bn, targeting dominance in CML
30.03.2026 15:09
MSD’s acquisition of Terns Pharmaceuticals is a calculated, forward-looking manoeuvre to secure the next generation of haematology assets.
How Investors May Respond To Merck (MRK) WINREVAIR Phase 2 Success In Tough Heart Failure Segment
30.03.2026 13:08
Earlier this week, Merck & Co., Inc. reported detailed Phase 2 CADENCE results showing WINREVAIR (sotatercept-csrk) significantly reduced pulmonary vascular resistance in adults with combined post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction, with a safety profile generally in line with its use in pulmonary arterial hypertension. Beyond meeting its primary endpoint, WINREVAIR also showed encouraging trends in six-minute walk distance, cardiac...
Merck (MRK) Shares Up Significantly Since Jim Cramer Advised to “Stay the Course”
30.03.2026 11:07
Merck & Co., Inc. (NYSE:MRK) is one of Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks. Merck & Co., Inc. (NYSE:MRK) aims to make an entry into the weight loss drug market through the HS-10535 drug, which it licensed from Hanosh Pharmaceutical through a $2 billion agreement. The shares are up by 33% over […]
Cutaneous Squamous Cell Carcinoma (cSCC) Market Rises to $8.33 Billion in 2026: Roche, Merck & Co., and Sanofi Leads the Industry
30.03.2026 09:57
Key opportunities include non-surgical treatments, outpatient procedures, and global expansion, particularly in Asia-Pacific. Major players are focusing on immuno-oncology advancements. Cutaneous Squamous Cell Carcinoma (cSCC) Market Cutaneous Squamous Cell Carcinoma (cSCC) Market Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Cutaneous Squamous Cell Carcinoma (cSCC) Market Report 2026" has been added to ResearchAndMarkets.com's offering. The cutaneous squamous cell carcinoma (cSCC) market is s
Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline
30.03.2026 09:51
The market offers key opportunities through the growth of personalized therapies, adoption of monoclonal antibodies, digital health integration, and innovative solutions like irinotecan liposome injections. Rising incidence and need for improved treatments fuel this sector's potential. Pancreatic Adenocarcinoma Treatment Market Pancreatic Adenocarcinoma Treatment Market Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Pancreatic Adenocarcinoma Treatment Market Report 2026" has been added to Resea
Esophageal Cancer Market to Grow from $1.65 Billion in 2026 to $2.37 Billion by 2030: Pfizer, Roche, Merck & Co. Dominate
30.03.2026 09:00
Emphasis on personalized care, minimally invasive procedures, and addressing unmet needs through product innovation is driving industry growth Esophageal Cancer Market Esophageal Cancer Market Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Esophageal Cancer Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global esophageal cancer market is poised for substantial growth, evolving from $1.51 billion in 2025 to an anticipated $1.65 billion by 2026, reflecting a compound
Reported Sunday, Merck's Winrevair Demonstrates Statistically Significant 1.02 Wood Units Reduction In PVR In Phase 2 CADENCE Trial, Paving Way For Phase 3 Study
30.03.2026 02:05
Merck's WINREVAIR met primary endpoint of change in pulmonary vascular resistance (PVR), significantly improving the ability of blood to flow through the lungs to the heartTotality of evidence across hemodynamic,
Merck: Aggressive M&A Efforts To Prepare For A Keytruda Patent Cliff
29.03.2026 09:29
Merck expands oncology via $5.7B Terns deal, but Keytruda dependence and 2028-29 patent cliff raise risk; review debt, valuation, and dividend before buying.
Merck & Co. Touts $6.7B Terns Deal, Highlights TERN-701 “Best-in-Class” CML Potential
28.03.2026 07:20
Merck & Co., Inc. (NYSE:MRK) held an investor event to discuss its planned acquisition of Terns Pharmaceuticals, emphasizing the strategic rationale, clinical data to date for Terns’ lead asset, and the financial terms of the deal. Deal rationale centers on TERN-701 and Merck’s hematology ambit
RBC Capital Lowers Exelixis (EXEL) Price Target to $43
28.03.2026 07:18
Exelixis, Inc. (NASDAQ:EXEL) is one of the 15 Set-It-and-Forget-It Stocks to Buy in 2026. On March 2, 2026, Exelixis, Inc. (NASDAQ:EXEL) saw its price target from RBC Capital lowered from $46 to $43. The firm’s Sector Perform rating was maintained on the stock. In a research note, RBC Capital pointed out that after the reporting […]